reardon: search

Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme

Bradmer Pharmaceuticals Inc. announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor Center at Duke University under direction of Dr. David Reardon as Principal Investigator.

Search took 0.00 seconds.